MedStar Health & PathAI Expand Digital Pathology Network with AISight Dx & AI Deployment

MedStar Health will also adopt several AI-based pathology applications, including ArtifactDetect, which is designed to identify slide preparation and scanning issues during workflow, and TumorDetect, an AI model.

MedStar Health, a US-based healthcare organization and PathAI, a Boston-based AI-powered pathology startup, have entered into a multi-year strategic collaboration to deploy the AISight Dx digital pathology platform and multiple AI algorithms across MedStar Health’s laboratory network, expanding digital pathology capabilities for more than 40 pathologists across the health system.

Under the agreement, MedStar Health will implement PathAI’s AISight Dx platform, a cloud-native digital pathology image management system designed to support clinical, laboratory, and research operations.

The platform has received U.S. Food and Drug Administration clearance for primary diagnosis and combines enterprise-scale slide management, image viewing, collaboration tools, and AI integration in a single system.

As part of the deployment, MedStar Health will also adopt several AI-based pathology applications, including ArtifactDetect, which is designed to identify slide preparation and scanning issues during workflow, and TumorDetect, an AI model currently designated for research use only.

The tools are intended to improve pathology workflow efficiency and help standardize laboratory processes across MedStar’s multi-site network.

“At MedStar Health, we are focused on scaling high-quality care across a large and growing health system, including a rapidly expanding outreach business, and digital pathology is a critical enabler of that mission,” said Moira Larsen, MD, physician executive director of MedStar Medical Group Pathology at MedStar Health.

“By deploying AISight Dx and advanced AI applications, we are modernizing our pathology infrastructure in a way that makes us more connected, more efficient, and better positioned to bring innovative diagnostics into everyday practice.”

“Digital pathology and AI are transforming how health systems generate insight and scale impact,” says Nick Brown, chief growth officer of PathAI. “Through our collaboration with MedStar Health, we’re building a modern digital infrastructure that will accelerate innovation and future-proof MedStar’s pathology growth.”

The collaboration builds on MedStar Health’s previous participation in PathAI’s Early Access Program and follows prior joint research efforts, including an independent validation study involving PathAI’s AIM-HER2 Breast algorithm.

It is also expected to include joint research initiatives, development of multimodal real-world datasets, support for clinical trials, and work on future AI-enabled diagnostic tools.

Stay tuned for more such updates on Digital Health News